Pfizer/BioNTech show high immune response in a booster dose against Omicron in clinical trial for children 5-11 years

Article

Pfizer/BioNTech announce positive results for a third dose of their COVID-19 vaccine for children

Grant Paulsen, MD, assistant professor, Division of Infectious Disease, Department of Pediatrics, Cincinnati Children's Hospital Medical Center in Ohio, and primary investigator for the hospital's clinical trial for a third dose (booster) for the Pfizer/BioNTech vaccine for COVID-19, discusses what the data might mean for children aged 5 to 11 years.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe Now!
Recent Videos
Potential downstream benefits of RSV preventive measures, with Octavio Ramilo, MD
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
Octavio Ramilo, MD, reacts to the FDA approval of clesrovimab for RSV prevention | Image Credit: St. Jude Children's Research Hospital
Tina Tan, MD, comments on FDA expanded approval for MenQuadfi meningococcal disease vaccine
Tina Tan, MD, discusses impact of FDA's stricter COVID-19 vaccine policy for children
Related Content
FDA-approved berdazimer gel, 10.3% launches to treat molluscum contagiosum | Image Credit: © syahrir - ©syahrir - stock.adobe.com.

FDA-approved berdazimer gel, 10.3% launches to treat molluscum contagiosum

Joshua Fitch, Senior Editor
July 10th 2025
Article

The nitric oxide–releasing topical is the first prescription medication approved for at-home treatment of molluscum contagiosum.

What's going on with polio, monkeypox, and COVID-19

What's going on with polio, monkeypox, and COVID-19

Miranda Hester
August 19th 2022
Podcast

The news is full of stories about monkeypox, the recent changes to COVID-19 guidance, and the return of polio cases. What do clinicians need to know?

FDA accepts NDA for ET-600, desmopressin oral solution for pediatric AVP deficiency | © Contemporary Pediatrics

FDA accepts NDA for ET-600, desmopressin oral solution for pediatric AVP deficiency

Morgan Ebert, Managing Editor
July 8th 2025
Article

The FDA accepted Eton Pharmaceuticals' NDA for ET-600 for pediatric arginine vasopressin deficiency, with a target action date in February of 2026.

What Omicron could mean for the pandemic

What Omicron could mean for the pandemic

Miranda Hester
January 7th 2022
Podcast

Contemporary Pediatrics sat down with Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, to discuss what's known about the variant. She also discusses the latest on the vaccine for children aged younger than 5 years.

FDA approves sebetralstat as first and only on-demand treatment for HAE | Image Credit: Contemporary Pediatrics

FDA approves sebetralstat as first and only on-demand treatment for HAE

Joshua Fitch, Senior Editor
July 7th 2025
Article

Though the original target action date was not met by the FDA, KalVista's sebetralstat is now approved to treat HAE in patients 12 years and older.

Key FDA approvals in pediatric health: First half of 2025 | Image Credit: © Postmodern Studio - stock.adobe.com.

Key FDA approvals in pediatric health: First half of 2025

Morgan Ebert, Managing Editor
July 5th 2025
Article

A roundup of the most impactful FDA approvals in pediatric health from January through June 2025, spanning diagnostics, therapeutics, and at-home care.

© 2025 MJH Life Sciences

All rights reserved.